Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.

Sonpavde G, Willey CD, Sudarshan S.

Expert Opin Investig Drugs. 2014 Mar;23(3):305-15. doi: 10.1517/13543784.2014.871259. Epub 2014 Jan 3. Review.

PMID:
24387233
2.

Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.

Saylor PJ, Escudier B, Michaelson MD.

Clin Genitourin Cancer. 2012 Jun;10(2):77-83. doi: 10.1016/j.clgc.2012.01.010. Epub 2012 Feb 28. Review.

PMID:
22382009
3.

Angiogenesis and angiogenic inhibitors in renal cell carcinoma.

Sawhney R, Kabbinavar F.

Curr Urol Rep. 2008 Jan;9(1):26-33. Review.

PMID:
18366971
4.

Sunitinib, sorafenib and mTOR inhibitors in renal cancer.

Radulovic S, Bjelogrlic SK.

J BUON. 2007 Sep;12 Suppl 1:S151-62. Review.

PMID:
17935273
5.

Targeting angiogenesis in renal cell carcinoma.

Posadas EM, Limvorasak S, Sharma S, Figlin RA.

Expert Opin Pharmacother. 2013 Nov;14(16):2221-36. doi: 10.1517/14656566.2013.832202. Epub 2013 Aug 28. Review.

PMID:
23984807
6.

Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma.

Massari F, Ciccarese C, Santoni M, Lopez-Beltran A, Scarpelli M, Montironi R, Cheng L.

Expert Rev Anticancer Ther. 2015;15(12):1367-9. doi: 10.1586/14737140.2015.1110488. Epub 2015 Nov 14.

PMID:
26568023
7.

The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.

Ronca R, Giacomini A, Rusnati M, Presta M.

Expert Opin Ther Targets. 2015;19(10):1361-77. doi: 10.1517/14728222.2015.1062475. Epub 2015 Jun 30. Review.

PMID:
26125971
8.

Novel tyrosine kinase inhibitors for renal cell carcinoma.

Dorff TB, Pal SK, Quinn DI.

Expert Rev Clin Pharmacol. 2014 Jan;7(1):67-73. doi: 10.1586/17512433.2014.862496. Epub 2013 Dec 2. Review.

PMID:
24308791
9.

Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.

Heng DY, Bukowski RM.

Curr Cancer Drug Targets. 2008 Dec;8(8):676-82. Review.

PMID:
19075590
10.

Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.

Hutson TE, Sonpavde G, Galsky MD.

Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S31-9. Review.

PMID:
17239282
11.

Targeted agents for the treatment of advanced renal cell carcinoma.

Staehler M, Rohrmann K, Haseke N, Stief CG, Siebels M.

Curr Drug Targets. 2005 Nov;6(7):835-46. Review.

PMID:
16305462
12.

Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.

Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A.

BJU Int. 2007 Feb;99(2):274-80. Epub 2006 Dec 1. Review.

13.

Understanding the importance of smart drugs in renal cell carcinoma.

Patard JJ, Rioux-Leclercq N, Fergelot P.

Eur Urol. 2006 Apr;49(4):633-43. Epub 2006 Feb 2. Review.

PMID:
16481093
14.
15.

Pazopanib for the treatment of renal cancer.

Al-Marrawi MY, Rini B.

Expert Opin Pharmacother. 2011 May;12(7):1171-89. doi: 10.1517/14656566.2011.571206. Epub 2011 Apr 7. Review. Erratum in: Expert Opin Pharmacother. 2011 Jun;12(8):1349.

PMID:
21470066
16.

The emerging role of nuclear factor kappa B in renal cell carcinoma.

Morais C, Gobe G, Johnson DW, Healy H.

Int J Biochem Cell Biol. 2011 Nov;43(11):1537-49. doi: 10.1016/j.biocel.2011.08.003. Epub 2011 Aug 12. Review.

PMID:
21854869
17.

Sunitinib malate for the treatment of renal cell carcinoma.

Wood L.

Expert Opin Pharmacother. 2012 Jun;13(9):1323-36. doi: 10.1517/14656566.2012.689130. Review.

PMID:
22607009
18.

Targeted agents for the treatment of advanced renal cell carcinoma.

Stadler WM.

Cancer. 2005 Dec 1;104(11):2323-33. Review.

19.

Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.

Zivi A, Cerbone L, Recine F, Sternberg CN.

Expert Opin Drug Saf. 2012 Sep;11(5):851-9. doi: 10.1517/14740338.2012.712108. Epub 2012 Aug 4. Review.

PMID:
22861374
20.

Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.

Tang PA, Vickers MM, Heng DY.

Hematol Oncol Clin North Am. 2011 Aug;25(4):871-91. doi: 10.1016/j.hoc.2011.04.003. Review.

PMID:
21763972
Items per page

Supplemental Content

Write to the Help Desk